WALTHAM, Mass., June 26, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has enrolled the first patient in its corneal wound repair pivotal study in patients having undergone photorefractive keratectomy (“PRK”) surgery.
Barbara Wirostko MD, Chief Medical Officer of EyeGate, said, “There is a significant need for an effective and accessible Hyaluronic Acid (“HA”) eyedrop formulation in the U.S. that can help re-epithelialize corneal defects due to surgery, injuries, and diseases. We believe our OGB platform would be the first to address that unmet need. We are extremely pleased with the efficiency of our team and sites in getting this trial underway and we expect to remain on track to receive topline results by year-end 2019. Following the topline data readout, we plan to submit the de novo application for commercialization with the ultimate goal of getting a product to market in 2020.”
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company focused on
developing and commercializing products using its two proprietary platform
technologies for treating diseases and disorders of the eye.
EyeGate’s OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.
EGP-437, EyeGate’s other product in clinical development, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. For more information, please visit www.EyeGatePharma.com.
EyeGate Social
Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page
(https://www.facebook.com/ EyeGatePharma/), corporate Twitter account
(https://twitter.com/EyeGatePharma), and LinkedIn page
(https://www.linkedin.com/company/135892/) as channels of distribution of
information about EyeGate and its product candidates. Such information may be
deemed material information, and EyeGate may use these channels to comply with
its disclosure obligations under Regulation FD. Therefore, investors should monitor
EyeGate’s website and its social media accounts in addition to following its
press releases, SEC filings, public conference calls, and webcasts. The social
media channels that EyeGate intends to use as a means of disclosing the
information described above may be updated from time to time as listed on
EyeGate’s investor relations website.
Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made
pursuant to the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These “forward-looking” statements include statements
relating to, among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s products,
including EyeGate’s OBG product, its EGP-437 Combination Product, as well as
the success thereof, with such approvals or success may not be obtained or
achieved on a timely basis or at all. These statements involve risks and
uncertainties that may cause results to differ materially from the statements
set forth in this press release, including, among other things, certain risk
factors described under the heading “Risk Factors” contained in EyeGate’s
Annual Report on Form 10-K filed with the SEC on March 1, 2019 or described in
EyeGate’s other public filings. EyeGate’s results may also be affected by
factors of which EyeGate is not currently aware. The forward-looking statements
in this press release speak only as of the date of this press release. EyeGate
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in its
expectations with regard thereto or any changes in the events, conditions or
circumstances on which any such statement is based.
Contact
Joseph Green / Laine Yonker
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030 / 7035
jgreen@edisongroup.com / lyonker@edisongroup.com